Off-label and unlicensed prescribing for children
Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example
A population pharmacokinetic approach to ceftazidime use in burn patients
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease
Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia
Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or β-blockers and the risk of atherosclerosis
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects
Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain
Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?
Attitudes and experiences of community pharmacists towards paediatric off-label prescribing
No association between CYP2D6 polymorphisms and personality trait in Japanese
Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes
Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years
Risk of stent thrombosis after sirolimus or paclitaxel eluting coronary stent implantation
Glimepiride-induced vasculitis
Oxford Handbook of Nurse Prescribing
John Trounce
Erratum